亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會(huì)員第1年

無錫同創(chuàng)生物科技有限公司  

辣根過氧化物酶,5-溴-4氯-3吲哚-神經(jīng)氨酸,吡咯酯等

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:張倩
  • 電話:13655185676
  • 郵件:wuxitongchuang@yahoo.cn
  • 傳真:0510-85899582
  • QQ:1760363918
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 雙甘氨肽 556-50-3
雙甘氨肽 556-50-3
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 江蘇無錫市付款后3天內(nèi)
過期 長(zhǎng)期有效
更新 2024-01-10 11:53
 
詳細(xì)信息

中文名稱:雙甘肽

英文名字:Glycylglycine

CAS:556-50-3

分子式:C4H8N2O3

分子量: 132.12

規(guī)格:25KG/桶

質(zhì)量標(biāo)準(zhǔn):

外觀:白色結(jié)晶粉末

熔點(diǎn):220-240℃

溶解度(1M 水溶液):無色、澄清

含量:≥99%

產(chǎn)品應(yīng)用:在生物研究及醫(yī)藥上用作血液保存和蛋白質(zhì)藥物細(xì)胞色素C水針劑的穩(wěn)定劑。

©2025 無錫同創(chuàng)生物科技有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:36449  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |